It's relatively cheap for the US to do since we made the catastrophic mistake of depending on Emergent BioSolutions to make the vaccine in the US, so all our ra

It's relatively cheap for the US to do since we made the catastrophic mistake of depending on Emergent BioSolutions to make the vaccine in the US, so all our raw doses are coming from a Janssen plant in the Netherlands and we've run out of the "banked" doses made before FDA Emergency Use Authorization. What I'm finding interesting is that if this has anything in common with the (AZ/)Oxford vaccine problem as we should suspect, it would not seem to be related to Oxford's unique or nearly so use of an unstabilized version of the spike protein. At this point the only things obviously in common are some version of the spike protein and using adenovirus vectors. Different ones of the latter, a chimpanzee derived one for Oxford and a normal human one that's one of the causes of "the common cold" for Janssen. Derek Lowe has commentary from yesterday on all this here, up to date except it only mentioned Janssen in passing based on his hearing about early cases with the latter: https://blogs.sciencemag.org/pipeline/archives/2021/04/12/az-oxford-calculations https://blogs.sciencemag.org/pipeline/archives/2021/04/12/az... It goes into the cold risk/benefit calculations you should make for various treatments and their diseases.